Prediagnostic aspirin use and mortality in women with stage I to III breast cancer: A cohort study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Cancer

Volumn 122, Issue 13, 2016, Pages 2067-2075

  Bradley, Marie C ^a   Black, Amanda ^a   Freedman, Andrew N ^a   Barron, Thomas I ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

aspirin; breast cancer mortality; lymph node metastasis; postmenopausal; Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MIDDLE AGED; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; UNITED STATES; BREAST NEOPLASMS; CLINICAL TRIAL; LYMPH NODE; MORTALITY; MULTICENTER STUDY; PATHOLOGY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

AGED; ASPIRIN; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; LYMPH NODES; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS;

EID: 84964974576     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.30004     Document Type: Article

References (28)

1. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377:31-41.
2. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet. 2012;379:1602-1612.
3. Blair CK, Sweeney C, Anderson KE, Folsom AR. NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat. 2007;101:191-197.
4. Kwan ML, Habel LA, Slattery ML, Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 2007;18:613-620.
5. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28:1467-1472.
6. Wernli KJ, Hampton JM, Trentham-Dietz A, Newcomb PA. Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors. Pharmacoepidemiol Drug Saf. 2011;20:131-137.
7. Li Y, Brasky TM, Nie J, et al. Use of nonsteroidal anti-inflammatory drugs and survival following breast cancer diagnosis. Cancer Epidemiol Biomarkers Prev. 2012;21:239-242.
8. Holmes MD, Olsson H, Pawitan Y, et al. Aspirin intake and breast cancer survival-a nation-wide study using prospectively recorded data in Sweden. BMC Cancer. 2014;14:391.
9. Murray LJ, Cooper JA, Hughes CM, Powe DG, Cardwell CR. Post-diagnostic prescriptions for low-dose aspirin and breast cancer-specific survival: a nested case-control study in a breast cancer cohort from the UK Clinical Practice Research Datalink. Breast Cancer Res. 2014;16:R34.
10. Fraser DM, Sullivan FM, Thompson AM, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer. 2014;111:623-627.
11. Barron TI, Flahavan EM, Sharp L, Bennett K, Visvanathan K. Recent prediagnostic aspirin use, lymph node involvement, and 5-year mortality in women with stage I-III breast cancer: a nationwide population-based cohort study. Cancer Res. 2014;74:4065-4077.
12. Barron TI, Murphy LM, Brown C, Bennett K, Visvanathan K, Sharp L. De novo post-diagnosis aspirin use and mortality in women with stage I-III breast cancer. Cancer Epidemiol Biomarkers Prev. 2015;24:898-904.
13. Ng K, Meyerhardt JA, Chan AT, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015;107:345.
14. Prorok PC, Andriole GL, Bresalier RS, et al; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(suppl 6):273S-309S.
15. Knol MJ, VanderWeele TJ. Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol. 2012;41:514-520.
16. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology. 1999;10:37-48.
17. Daniel RM, Cousens SN, De Stavola BL, Kenward MG, Sterne JA. Methods for dealing with time-dependent confounding. Stat Med. 2013;32:1584-1618.
18. DerSimonian R, Laird N. Meta-analysis inclinical trials. Control Clin Trials. 1986;7:177-88.
19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
20. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW Jr. Aspirin use and risk of fatal cancer. Cancer Res. 1993;53:1322-1327.
21. Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E. Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004;24(5B):3177-3184.
22. Jacobs EJ, Newton CC, Gapstur SM, Thun MJ. Daily aspirin use and cancer mortality in a large US cohort. J Natl Cancer Inst. 2012;104:1208-1217.
23. Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol. 2012;30:3468-3477.
24. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA. 2009;302:649-658.
25. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet. 2012;379:1591-1601.
26. Cuzick J, Thorat MA, Bosetti C, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol. 2015;26:47-57.
27. Soni A. Aspirin Use Among the Adult US Noninstitutionalized Population, With and Without Indicators of Heart Disease, 2005. Rockville, MD: Agency for Healthcare Research and Quality; 2007.
28. Shebl FM, Sakoda LC, Black A, et al. Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer. 2012;107:207-214.